Even as market watchers debate whether H.B. Fuller (NYSE:FUL) made the right call in turning down Ancora’s $1.2 billion offer for its Building Adhesive Solutions segment, the specialty adhesive maker’s long-term investment thesis hinges on internal self-help over raw top-line expansion. Fundamentally, H.B. Fuller presents a story of aggressive margin optimization, backed by solid year-to-date operating cash flow generation, steady leverage reduction to improve balance sheet health, and structural footprint rationalization designed to maximize long-term return on invested capital and free cash flow conversion despite multi-year macro growth headwinds.
That internal operational engine was on full display when H.B. Fuller reported its fiscal third-quarter results on September 24. Headline revenue rose 5.2% year-over-year to $938 million, accompanied by a 21% surge in adjusted EPS and a raised full-year outlook. However, a deeper look reveals that this financial performance was powered almost exclusively by pricing power and cost discipline rather than underlying volume expansion—linking directly to the company’s core driver of squeezing more profit out of a stagnant top line.
Pricing Carries The Quarter
Organic revenue rose 4.4% during the quarter, with a 7.4% price increase doing the heavy lifting to offset a 3% decline in sales volume. Adjusted EBITDA grew 9% to $187 million, while adjusted EBITDA margin expanded 80 basis points to 19.9%, bringing the company within striking distance of management’s long-sought 20% target. Every operating segment contributed to top-line gains: Hygiene, Health and Consumable Adhesives grew 6% on strength in hygiene and beverage labeling; Building Adhesive Solutions grew 5% on roofing and insulating glass demand; and Engineering Adhesives grew 5% (excluding solar) supported by ongoing aerospace strength. Internationally, performance was even stronger, led by a 9% rise in the EIMEA region, prompting CEO Celeste Mastin to note that “Europe is looking up.”
Behind the margin expansion lies a structural overhaul of H.B. Fuller’s manufacturing footprint. The company has reduced its plant count from 82 facilities in 2024 to approximately 62 by the end of this year, with a long-term target of 55 facilities. Under its “Quantum Leap” initiative, management expects these efficiency measures to yield $75 million in annualized cost savings by 2030. Reflecting these operational gains, full-year guidance was raised to $655 million–$670 million in adjusted EBITDA and $4.70–$4.85 in adjusted EPS. Cash flow from operations rose 17% year-to-date to $183 million, while net debt to EBITDA improved to 3.0x from 3.3x a year ago. Meanwhile, the pending acquisition of Advanced Medical Solutions/AMS remains on track to close before year-end, positioning the combined business as the second-largest surgical tissue bonding provider globally.
Volume Keeps Sliding
The key vulnerability in H.B. Fuller’s operational story is that customer demand continues to contract, marking a third consecutive quarter of shrinking volumes. Engineering Adhesives experienced softening demand in electronics as chip shortages constrained mobile phone manufacturing in the Asia-Pacific region, a sharp reversal from the segment’s strong performance in the first half of the year. Additionally, management highlighted that ordering patterns among small and mid-sized customers are fluctuating more than usual, increasing forecasting uncertainty.
Supply chain bottlenecks and input cost pressures also remain persistent. Mastin described ongoing petrochemical supply disruptions as a defining feature of the current operating environment, noting that normalization is unlikely until underlying geopolitical conflicts subside, keeping raw material costs elevated. To protect supply continuity, net working capital expanded 150 basis points to 18.5% of annualized revenue as inventory was built up, while SG&A expenses grew 8%. Looking ahead to 2027, management singled out China as an area of concern due to a weak domestic consumer market and softer electronics exports. Furthermore, leverage will need to be reduced back to a target range of 2.5x to 3.0x within two years of the AMS transaction closing, pointing to potential near-term balance sheet strain from acquisition financing.
A Cheap Stock With Doubters
Institutional positioning reflects an interesting split sentiment. Hedge fund ownership climbed from 23 funds to 28 funds in the most recent quarter, indicating building institutional interest in the company’s margin execution. Conversely, short interest stands at 7.44% of float, representing a sizable bear camp focused on broader demand weakness.
This short interest is primarily driven by skepticism over whether pricing increases can indefinitely offset declining volumes, alongside concerns regarding temporary balance sheet leverage following the AMS deal. Meanwhile, the stock trades at a forward P/E multiple of just 9.44x, as of September 24. Evaluated against core investor questions, does this single-digit valuation make the stock cheap or a value trap? A forward P/E under 10x appears visually cheap for a business generating 19.9% EBITDA margins, $183 million in year-to-date operating cash flow, and compounding structural cost savings. However, the low valuation multiple indicates the market is discounting the sustainability of management’s margin expansion until organic volume growth turns positive.
Where This Leaves Investors
H.B. Fuller’s third-quarter results highlight two opposing dynamics: an effective pricing and restructuring model driving margin expansion, set against a softer end-market environment where physical volume is declining. For bullish investors, the remaining cost savings from the Quantum Leap program and the strategic addition of AMS provide a clear pathway for continued margin expansion and earnings compounding.
For bearish investors, three consecutive quarters of volume contraction and ongoing raw material supply dislocations warrant caution regarding top-line sustainability. Trading at a single-digit forward P/E multiple, the stock’s valuation suggests the market is weighing these structural margin improvements against broader macro volume headwinds.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center